Kindred Biosciences, Inc. KIN
Day range unavailable
52-week range unavailable
- Market cap
- 420.53M
- Revenue (ttm)
- 5.78M
- Shares out
- 45.46M
- Forward P/E
- -132.14
- Beta
- 1.32
- Analysts
- Hold
- Price target
- 9.50 (+2.7%)
- Earnings date
- Aug 5, 2021
Key statistics
- Enterprise value
- 369.55M
- PEG ratio
- -0.33
- Price / sales
- 72.81
- Price / book
- 5.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 60.00%
- Free cash flow
- -15.18M
- Total cash
- 74.20M
- Total debt
- 23.23M
- Return on equity
- -50.36%
- Short % of float
- 3.03%
- 50-day average
- 9.20
- 200-day average
- 6.64
Analyst view
Consensus: hold
- Target (low)
- 9.00
- Target (mean)
- 9.50
- Target (high)
- 11.00
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 5, 2021
Expected Aug 5, 2021. Consensus EPS estimate -0.16.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2021 | Jun 1, 2021 | -0.12 | — | — | — |
| May 11, 2021 | Mar 1, 2021 | -0.22 | — | — | — |
| Mar 16, 2021 | Dec 1, 2020 | -0.33 | — | — | — |
| Nov 9, 2020 | Sep 1, 2020 | -0.31 | — | — | — |
| Aug 5, 2020 | Jun 1, 2020 | 0.15 | — | — | — |
| May 7, 2020 | Mar 1, 2020 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 17, 2021 | Lake Street | down | Buy | Hold |
| Jun 17, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 16, 2021 | Aegis Capital | down | Buy | Hold |
| Jan 26, 2021 | Aegis Capital | main | — | Buy |
| Jul 29, 2020 | Cantor Fitzgerald | main | — | Overweight |
| Mar 17, 2020 | Stifel | main | — | Buy |
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. As of August 27, 2021, Kindred Biosciences, Inc. operates as a subsidiary of Elanco Animal Health Incorporated.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- kindredbio.com
News
SHAREHOLDER ALERT: WeissLaw LLP Reminds CVA, SWN, RIVE, and KIN Shareholders About Its Ongoing Investigations 
Moore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law Firm 
KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN 
Stocks That Hit 52-Week Highs On Thursday 
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN 
Why Kindred Biosciences Stock Skyrocketed Today 
Kindred Biosciences to merge with Elanco Animal Health 
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today 
Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KIN 
Stocks That Hit 52-Week Highs On Wednesday
Your note
Sign in to keep a note on KIN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEVERS DENISE M. | Director | Sale | Mar 16, 2021 | 0 |
| CHIN RICHARD | Chief Executive Officer | Sale | Jul 1, 2021 | 1,894,270 |
| MARIO ERNEST B | Director | Conversion of Exercise of derivative security | Oct 28, 2018 | 169,000 |
| NODELMAN OLEG | Director | Purchase | Sep 28, 2014 | 0 |
| PARK WEST ASSET MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 3, 2021 | 0 |
| SCHULTZ KEVIN THOMAS PH.D. | Officer | Purchase | Dec 11, 2013 | 4,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Park West Asset Management LLC | 13.20% | 6,000,002 | 55.02M | Jun 29, 2021 |
| Magnetar Financial LLC | 7.55% | 3,431,998 | 31.47M | Jun 29, 2021 |
| Millennium Management LLC | 6.05% | 2,751,857 | 25.23M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 4.16% | 1,890,913 | 17.34M | Jun 29, 2021 |
| FIL LTD | 3.98% | 1,810,000 | 16.60M | Jun 29, 2021 |
| Point72 Asset Management, L.P. | 3.56% | 1,620,476 | 14.86M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.56% | 1,164,425 | 5.79M | Mar 30, 2021 |
| JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd | 1.34% | 607,521 | 5.57M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 1.25% | 568,206 | 2.82M | Mar 30, 2021 |
| DFA U.S. Small Cap Series | 0.83% | 375,136 | 1.88M | Apr 29, 2021 |
| Fidelity Small Cap Index Fund | 0.71% | 324,534 | 1.57M | May 30, 2021 |
| DFA U.S. Micro Cap Series | 0.67% | 304,990 | 1.52M | Apr 29, 2021 |